Presence of NPM1 Mutation May Alleviate the Negative Prognostic Significance of AML with Myelodysplasia-Related Changes

被引：0
|
作者：
Pourabdollah, Maryam
Jiang, Gina [1 ]
Atenafu, Eshetu [2 ]
Chang, Hong
机构：
[1] Univ Hlth Network, Markham, ON, Canada
[2] Univ Hlth Network, Toronto, ON, Canada
来源：
MODERN PATHOLOGY | 2019年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
1362
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Fludarabine, High-Dose Cytarabine and Idarubicin-Based Induction May Overcome the Negative Prognostic Impact of FLT3-ITD in NPM1 Mutated AML, Irrespectively of FLT3-ITD Allelic Burden
    Minetto, Paola
    Candoni, Anna
    Guolo, Fabio
    Clavio, Marino
    Zannier, Maria Elena
    Miglino, Maurizio
    Dubbini, Maria Vittoria
    Carminati, Enrico
    Sicuranza, Anna
    Ciofini, Sara
    Colombo, Nicoletta
    Pugliese, Girolamo
    Marcolin, Riccardo
    Santoni, Adele
    Ballerini, Filippo
    Lanino, Luca
    Cea, Michele
    Gobbi, Marco
    Bocchia, Monica
    Fanin, Renato
    Lemoli, Roberto Massimo
    CANCERS, 2021, 13 (01) : 1 - 13
  • [42] ACUTE MYELOID LEUKEMIA (AML) PATIENTS HARBOURING BOTH, FLT3-ITD AND NPM1 MUTATION, MAY BENEFIT FROM A MINIMAL RESIDUAL DISEASES (MRD) GUIDED TRANSPLANT DECISION
    Schiller, J.
    Praulich, I.
    Hallek, M.
    Kreuzer, K.
    HAEMATOLOGICA, 2013, 98 : 22 - 23
  • [43] Prognostic significance of mutations of nucleophosmin (NPM1) gene and internal tandem duplication of FLT3 gene (FLT3 ITD) in acute myeloid leukemia (AML) with normal karyotype
    Brunet, S.
    Esteve, J.
    Nomdedeu, J.
    Ribera, J. M.
    Llorente, A.
    Duarte, R.
    Tormo, M.
    Guardia, R.
    Montserrat, E.
    Sierra, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [44] MINIMAL RESIDUAL DISEASE ASSESSED BY NPM1 MUTATION-SPECIFIC RQ-PCR ASSAYS HAS A PROGNOSTIC VALUE IN ACUTE MYELOID LEUKEMIA (AML) AND IS SIGNIFICANTLY DECREASED BY TREATMENT WITH GEMTUZUMAB OZOGAMICIN
    Lambert, J.
    Lambert, J.
    Nibourel, O.
    Pautas, C.
    Hayette, S.
    Cayuela, J. M.
    Terre, C.
    Dombret, H.
    Preudhomme, C.
    Castaigne, S.
    Renneville, A.
    HAEMATOLOGICA, 2012, 97 : 215 - 216
  • [45] Prognostic Significance of FLT3 and NPM1 Mutations in Adults of Age 18-60 with De Novo Acute Myeloid Leukemia (AML) on SWOG S0106 Study: A Study by FHCRC and SWOG
    Pogosova-Agadjanyan, Era L.
    Kopecky, Kenneth J.
    Petersdorf, Stephen
    Erba, Harry Paul
    Stone, Richard M.
    Meshinchi, Soheil
    Nevill, Thomas J.
    Radich, Jerald P.
    Stenke, Leif
    Slovak, Marilyn L.
    Stuart, Robert K.
    Tallman, Martin S.
    Willman, Cheryl L.
    Mortensen, Rebecca M.
    Wentz, Breanna L.
    Appelbaum, Frederick R.
    Stirewalt, Derek L.
    BLOOD, 2011, 118 (21) : 1080 - 1080
  • [46] Prognostic Impact of Mutations in the Nucleophosmin (NPM1) and of the FMS-Related Tyrosine Kinase 3 (FLT3) Genes in Elderly Patients with Acute Myeloid Leukemia (AML) Treated with Intensive Chemotherapy.
    Etienne, Anne
    Borel, Cecile
    Reutenauer, Sarah
    Olschwang, Sylviane
    Mozziconacci, Marie-Joelle
    Delabesse, Eric
    Demur, Cecile
    Prebet, Thomas
    Huguet, Francoise
    Charbonnier, Aude
    Recher, Christian
    Vey, Norbert
    BLOOD, 2008, 112 (11) : 883 - 883
  • [47] DNMT3A Mutation May Add Prognostic Value To Patients With Acute Myeloid Leukemia Of Intermediate Cytogenetic Risk Harboring a Favorable Genetic Profile Of NPM1, FLT3-ITD and CEBPA
    Pratcorona, Marta
    Diaz-Beya, Marina
    Nomdedeu, Meritxell
    Rozman, Maria
    Risueno, Ruth M.
    Esteve, Jordi
    BLOOD, 2013, 122 (21)
  • [48] Ratify (Alliance 10603): Prognostic Impact of FLT3 tyrosine Kinase Domain (TKD) and NPM1 Mutation Status in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Treated with Midostaurin or Placebo Plus Standard Chemotherapy
    Voso, Maria Teresa
    Larson, Richard A.
    Prior, Thomas
    Marcucci, Guido
    Jones, Dan
    Krauter, Juergen
    Heuser, Michael
    Lavorgna, Serena
    Nomdedeu, Josep
    Geyer, Susan M.
    Klisovic, Rebecca
    Wei, Andrew H.
    Sierra, Jorge
    Sanz, Miguel A.
    Brandwein, Joseph M.
    de Witte, Theo M.
    Jansen, Joop H.
    Niederweiser, Dietger
    Appelbaum, Frederick R.
    Medeiros, Bruno C.
    Tallman, Martin S.
    Schlenk, Richard F.
    Ganser, Arnold
    Amadori, Sergio
    Cheng, Yuan
    Gathmann, Insa
    Tiecke, Eva
    Thiede, Christian
    Doehner, Konstanze
    Doehner, Hartmut
    Stone, Richard M.
    Bloomfield, Clara D.
    Lo-Coco, Francesco
    BLOOD, 2018, 132
  • [49] Prognostic Impact of NPM1 and FLT3 Mutations at Diagnosis and Presence of Measurable Residual Disease (MRD) after Intensive Chemotherapy (IC) for Patients with Acute Myeloid Leukemia (AML) in Remission: Outcomes from the QUAZAR AML-001 Trial of Oral Azacitidine (Oral-AZA) Maintenance
    Dohner, Hartmut
    Wei, Andrew H.
    Roboz, Gail J.
    Montesinos, Pau
    Thol, Felicitas R.
    Ravandi, Farhad
    Dombret, Herve
    Porkka, Kimmo
    Sandhu, Irwindeep
    Skikne, Barry
    See, Wendy L.
    Ugidos, Manuel
    Risueno, Alberto
    Chan, Esther
    Thakurta, Anjan
    Beach, C. L.
    de Menezes, Daniel Lopes
    BLOOD, 2021, 138
  • [50] Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML
    Jae-Sook Ahn
    Hyeoung-Joon Kim
    Yeo-Kyeoung Kim
    Sung-Hoon Jung
    Deok-Hwan Yang
    Je-Jung Lee
    Nan Young Kim
    Seung Hyun Choi
    Chul Won Jung
    Jun-Ho Jang
    Hee Je Kim
    Joon Ho Moon
    Sang Kyun Sohn
    Jong-Ho Won
    Sung-Hyun Kim
    Dennis Dong Hwan Kim
    Annals of Hematology, 2016, 95 : 625 - 635
12345